Close Menu
    Facebook X (Twitter) Instagram
    Tuesday, November 17
    Top Stories:
    • Single-Cell Analysis Reveals Cas9’s On- and Off-Target Gene Effects
    • The CDC’s Most Nutrient-Dense Fruit Isn’t Blueberries or Oranges
    • Simple Daily Habit Linked to Less Pain and Depression
    Facebook X (Twitter) Instagram Pinterest Vimeo
    IO Tribune
    • Home
    • AI
    • Tech
      • Gadgets
      • Fashion Tech
    • Crypto
    • Smart Cities
      • IOT
    • Science
      • Space
      • Quantum
    • OPED
    IO Tribune
    Home » Capricor Surges Amid FDA Review Extension and New Amendments
    Science

    Capricor Surges Amid FDA Review Extension and New Amendments

    Lina Johnson MercilliBy Lina Johnson MercilliAugust 14, 2026No Comments3 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Essential Insights

    1. Capricor collaborates with the FDA to include open-label extension data for deramiocel.
    2. The FDA is considering a refined approval path despite committee’s previous rejection.
    3. The company halted other pipeline projects to focus on regulatory clarity for deramiocel.
    4. Capricor’s shares surged after announcing potential regulatory progress and data submission plans.

    FDA Review and Market Reaction

    Capricor Therapeutics is working closely with the FDA on its Duchenne muscular dystrophy cell therapy, deramiocel. Recently, the company suggested that the agency might consider adding new data to its current application. This news came after an advisory meeting where the FDA’s experts initially recommended against approval. However, the CEO stated that the FDA seems open to an alternative approval path. As a result, investors reacted positively, causing Capricor’s shares to jump 68%. The FDA has not yet confirmed these plans, but the company remains optimistic. The current review deadline is August 22. Overall, this update offers hope for faster progress in bringing the therapy to patients.

    Balancing Hope and Scientific Challenges

    The debate around deramiocel centers on whether the data shows enough benefit for approval. The Phase 3 trial involved 106 boys and men with Duchenne. It aimed to improve physical abilities, with the primary focus on upper limb movements. The results showed the therapy worked statistically for these functions. But the FDA questioned the validity of some findings, especially regarding the heart-related secondary endpoints. The agency argued that the data on heart function wasn’t strong enough to support approval. Despite these disagreements, the company emphasizes that the main goal—improving muscle strength—remained positive. Scientific challenges remain, but each step helps refine understanding and develop better treatments.

    Impact on Patients and Future Directions

    While the regulatory process continues, Capricor has halted its other projects to focus on deramiocel. This includes a COVID-19 vaccine candidate and other early-stage therapies. The company is also exploring ways to expand deramiocel to younger patients and those with related conditions like Becker muscular dystrophy, depending on the regulatory outcome. Meanwhile, discussions are underway for approval in international markets, with manufacturing facilities ready in the U.S. Despite the setbacks, the company’s ongoing efforts could eventually lead to new options for patients dealing with rare and difficult-to-treat diseases. This scenario highlights how scientific progress can be shaped by regulatory decisions, ultimately aiming to improve quality of life for those in need.

    Continue Your Tech Journey

    Learn how the Internet of Things (IoT) is transforming everyday life.

    Learn more about cutting-edge innovations supported by the National Science Foundation (NSF).

    Sci-BioV1

    Asia Biotech health Innovation Medical medicine Tech VT1
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleUnforgetful: The Reminders App for Chronic Snoozers
    Next Article China’s Wealthiest Province Leverages Alibaba for AI and Chip Innovation
    Avatar photo
    Lina Johnson Mercilli
    • Website

    Lina Johnson Marcelli is the editor for IO Tribune, bringing over two decades of experience in journalism to her role. With a BA in Journalism, she is passionate about delivering impactful stories that resonate with readers. Known for her keen editorial vision and leadership, Lina is dedicated to fostering innovative storytelling across the publication. Outside of work, she enjoys exploring new media trends and mentoring aspiring journalists.

    Related Posts

    Gadgets

    iPad Recovery Mode: How to Enter With or Without a Home Button

    November 17, 2026
    AI

    Trustworthy AI Needs Guardrails, Not Predictions

    November 16, 2026
    Science

    Single-Cell Analysis Reveals Cas9’s On- and Off-Target Gene Effects

    November 16, 2026
    Add A Comment

    Comments are closed.

    Must Read

    iPad Recovery Mode: How to Enter With or Without a Home Button

    November 17, 2026

    Trustworthy AI Needs Guardrails, Not Predictions

    November 16, 2026

    Single-Cell Analysis Reveals Cas9’s On- and Off-Target Gene Effects

    November 16, 2026

    Open-Source Community Wants Jensen Huang Back

    November 16, 2026

    Earth’s Oxygen Rise May Have Happened Differently Than We Thought

    November 16, 2026
    Categories
    • AI
    • Crypto
    • Fashion Tech
    • Gadgets
    • IOT
    • OPED
    • Quantum
    • Science
    • Smart Cities
    • Space
    • Tech
    Most Popular

    The Atlantic’s Impact on the Pacific’s Mighty Current

    June 15, 2026

    Galaxy S26 Teaser: Privacy Display Battles Shoulder Surfers!

    February 16, 2026

    CoinFello’s Vision: Powering the Future of DeFi

    June 24, 2026
    Our Picks

    $147K Daily: Base Leads L2 Fees as Most Chains Struggle Under $5K

    January 18, 2026

    The Universe Unplugged: Unraveling the Mysteries of the Cosmos

    January 7, 2026

    ‘Can B Corp Still Signal Genuine Care in Fashion?’

    August 16, 2025
    Categories
    • AI
    • Crypto
    • Fashion Tech
    • Gadgets
    • IOT
    • OPED
    • Quantum
    • Science
    • Smart Cities
    • Space
    • Tech
    • Privacy Policy
    • Disclaimer
    • Terms and Conditions
    • About Us
    • Contact us
    Copyright © 2025 Iotribune.comAll Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.